All In MedTech

Device Trial Radar · NCT04414891

Non Invasive Ventilation With NAVA vs ASV for AECOPD

A Randomized Controlled Trial of Non-invasive Ventilation With Adaptive Support Ventilation Versus Neurally Adjusted Ventilator Assist in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Last checked: Nov 20, 2026Latest source record: Aug 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

76

Actual

Start

Dec 1, 2019

Primary completion

Dec 31, 2020

Study completion Dec 31, 2020

Sponsor

Sponsor type
Academic, hospital or other
First posted
Jun 4, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Non invasive ventilation is the standard of care in managing patients with exacerbation of chronic obstructive pulmonary disease. However no optimal mode of NIV delivery is established; failure rates remain high, attributed to asynchrony and leak associated with NIV. Neurally adjust ventilator assist is a new mode that may improve patient ventilator interactions, improve synchrony and contribute to improved outcomes. Likewise ASV is a mode principled on the closed loop system and is associated with reduction of work associated with breathing and improved outcomes. In this randomised, non-blinded trial, we study these two modes of NIV delivery in patients of AECOPD with hypothesis being that better synchrony with NAVA may translate to better clinical outcomes.

Conditions

  • Acute Exacerbation of COPD

Interventions

  • Non invasive ventilationDevice

    Non invasive ventilation will be delivered using an oro-facial interface in both arms. NIV NAVA will be administered using Servo-i ventilator (Maquet, Getinge Group, Sweden) with software to compensate for air leaks. ASV arm will receive NIV using a Galileo GOLD ventilator (Hamilton Medical, AG, Switzerland).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of NIV failureTime frame: From initiation of NIV to either intubation or re-initiation of NIV or successful weaning

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Respiratory Intensive Care Unit, PGIMER

    Chandigarh, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.